| Literature DB >> 22558450 |
Ji-An Liang1, Li-Min Sun, Kuan-Pin Su, Shih-Ni Chang, Fung-Chang Sung, Chih-Hsin Muo, Chia-Hung Kao.
Abstract
BACKGROUND: The aim of this study was to evaluate a possible association between malignancy and anxiety disorders (AD) in Taiwan.Entities:
Mesh:
Year: 2012 PMID: 22558450 PMCID: PMC3338669 DOI: 10.1371/journal.pone.0036370
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics between anxiety disorder group and non-anxiety disorder group in 2000–2002.
| Variables | Anxiety disorder | ||||
| No N = 96,104 | Yes N = 24,066 | ||||
| n | % | n | % | p-value | |
| Sex | 0.86 | ||||
| Women | 61,768 | 64.3 | 15,482 | 64.3 | |
| Men | 34,336 | 35.7 | 8,584 | 35.7 | |
| Age, years | 1.00 | ||||
| 30–44 | 29,292 | 27.0 | 7,323 | 26.9 | |
| 45–54 | 24,764 | 22.8 | 6,191 | 22.8 | |
| 55–64 | 18,029 | 16.6 | 4,524 | 16.6 | |
| ≥65 | 24,019 | 22.1 | 6,028 | 22.2 | |
| Mean (SD) | 54.0 | (14.3) | 54.1 | (13.9) | 0.94 |
| Urbanization level | <0.0001 | ||||
| 1 | 28,742 | 29.9 | 6,374 | 26.5 | |
| 2 | 27,506 | 28.6 | 6,785 | 28.2 | |
| 3 | 16,749 | 17.4 | 3,959 | 16.5 | |
| 4 | 12,966 | 13.5 | 4,020 | 16.7 | |
| 5 | 10,140 | 10.6 | 2,928 | 12.2 | |
| Co-morbidity | |||||
| Hypertension | 25,678 | 26.7 | 10,732 | 44.6 | <0.0001 |
| Diabetes mellitus | 9,089 | 9.5 | 2,798 | 11.6 | <0.0001 |
| Hyperlipidemia | 12,401 | 12.9 | 5,932 | 24.7 | <0.0001 |
Urbanization level: 1 indicate the highest level of urbanization and 5 the lowest
Chi-square test,
student T-test.
Hypertension: ICD-9-CM (A-code): 401–405 (A260 and A269), admission more than three times.
Diabetes mellitus: ICD-9-CM (A-code): 250 (A181), admission more than twice in the first year.
Hyperlipidemia: ICD-9-CM (A-code): 272 (A182), admission more than three times.
Comparisons of incidence density of cancer between anxiety disorder group and non-anxiety disorder group by characteristics.
| Anxiety disorder | ||||||||
| No | Yes | |||||||
| Variables | Cases | Person-years | Rate | Cases | Person-years | Rate | IRR | (95% CI) |
| All | 5,503 | 750,350 | 7.33 | 1,467 | 193,207 | 7.59 | 1.04 | (0.98–1.10) |
| Sex | ||||||||
| Women | 2,994 | 490,473 | 6.10 | 801 | 126,440 | 6.34 | 1.04 | (0.96–1.12) |
| Men | 2,509 | 259,877 | 9.65 | 666 | 66,767 | 9.97 | 1.03 | (0.95–1.13) |
| Age, years | ||||||||
| 30–44 | 563 | 240,916 | 2.34 | 169 | 61,461 | 2.75 | 1.18 | (0.99–1.40) |
| 45–54 | 1,087 | 204,396 | 5.32 | 290 | 51,421 | 5.64 | 1.06 | (0.93–1.21) |
| 55–64 | 1,298 | 144,457 | 8.99 | 341 | 36,672 | 9.30 | 1.03 | (0.92–1.17) |
| ≥65 | 2,555 | 160,581 | 15.9 | 667 | 43,653 | 15.3 | 0.96 | (0.88–1.05) |
| Urbanization level | ||||||||
| 1 | 1,502 | 227,091 | 6.61 | 364 | 51,455 | 7.07 | 1.07 | (0.96–1.20) |
| 2 | 1,562 | 216,528 | 7.21 | 388 | 54,886 | 7.07 | 0.98 | (0.88–1.10) |
| 3 | 906 | 130,615 | 6.94 | 228 | 31,686 | 7.20 | 1.04 | (0.90–1.20) |
| 4 | 851 | 99,830 | 8.52 | 269 | 32,156 | 8.37 | 0.98 | (0.86–1.13) |
| 5 | 682 | 76,276 | 8.94 | 218 | 23,024 | 9.47 | 1.06 | (0.91–1.23) |
| Co-morbidity | ||||||||
| Hypertension | ||||||||
| No | 3,314 | 565,762 | 5.86 | 609 | 109,651 | 5.55 | 0.95 | (0.87–1.03) |
| Yes | 2,189 | 184,589 | 11.9 | 858 | 83,556 | 10.3 |
|
|
| Diabetes mellitus | ||||||||
| No | 4,733 | 686,830 | 6.89 | 1,223 | 171,974 | 7.11 | 1.03 | (0.97–1.10) |
| Yes | 770 | 63,520 | 12.1 | 244 | 21,232 | 11.5 | 0.95 | (0.82–1.09) |
| Hyperlipidemia | ||||||||
| No | 4,609 | 654,514 | 7.04 | 1,060 | 145,678 | 7.28 | 1.03 | (0.97–1.10) |
| Yes | 894 | 95,836 | 9.33 | 407 | 47,528 | 8.56 | 0.92 | (0.82–1.03) |
per 1,000 person-year.
IRR: incidence rate ratio.
p<0.05,
p<0.001.
Hazard ratios and 95% confidence interval of cancer associated with anxiety disorder in Cox's regression analysis in different cancer.
| Percentage of cancer | ||||
| Variables | Non- Anxiety disorder | Anxiety disorder | HR | (95% CI) |
| Overall | 5.73 | 6.10 | 1.01 | (0.95–1.07) |
| Oral cancer | 0.26 | 0.26 | 0.81 | (0.40–1.61) |
| Colorectal cancer | 0.86 | 0.84 | 0.92 | (0.79–1.08) |
| Liver cancer | 0.72 | 0.85 | 1.11 | (0.95–1.30) |
| Lung cancer | 0.74 | 0.81 | 1.05 | (0.89–1.23) |
| Breast cancer (women only) | 0.98 | 1.16 | 1.32 | (0.95–1.34) |
| Cervical cancer (women only) | 0.35 | 0.25 | 0.72 | (0.51–1.03) |
| Prostate cancer (men only) | 0.66 | 1.00 |
|
|
| Other cancers | 2.06 | 2.08 | 1.00 | (0.88–1.15) |
ICD-9-CM: oral cancer, 140.xx–149.xx; colorectal cancer, 153.xx and 154.xx; liver cancer, 155.xx; lung cancer, 162.xx; breast cancer, 174.xx; cervical cancer, 180.xx; prostate cancer, 185.xx.
Adjusted for urbanization, hypertension, diabetes mellitus, and hyperlipidemia.
p-value<0.05,
p-value = 0.0678.
Multivariable Cox's regression analysis of cancer associated with anxiety disorder among age groups.
| Percentage of cancer | ||||
| Variables | Non-Anxiety disorder | Anxiety disorder | HR | (95% CI) |
| Prostate cancer (men only) | ||||
| 30–44 | 0.00 | 0.00 | – | |
| 45–54 | 0.16 | 0.10 | 0.46 | (0.10–2.14) |
| 55–64 | 0.75 | 0.98 | 1.25 | (0.68–2.29) |
| ≥65 | 1.63 | 2.66 |
|
|
| Cervical cancer (women only) | ||||
| 30–44 | 0.21 | 0.06 | 0.33 | (0.10–1.06) |
| 45–54 | 0.34 | 0.35 | 0.98 | (0.55–1.76) |
| 55–64 | 0.42 | 0.30 | 0.78 | (0.38–1.60) |
| ≥65 | 0.50 | 0.32 | 0.67 | (0.35–1.28) |
Adjusted for urbanization, hypertension, diabetes mellitus, and hyperlipidemia.
p<0.05,
p<0.001,
p<0.0001.
The distribution of prostate specific antigen and Papanicolaous smear between anxiety disorder group and non-anxiety disorder group.
| Anxiety disorder | |||||
| No | Yes | ||||
| Variable | n | % | n | (%) | p-value |
| PSA | |||||
| Age, year | |||||
| 30–44 | 294 | 2.92 | 197 | 7.83 | <0.0001 |
| 45–54 | 939 | 12.1 | 620 | 32.0 | <0.0001 |
| 55–64 | 1,546 | 25.2 | 709 | 46.2 | <0.0001 |
| ≥65 | 3,730 | 35.9 | 1,417 | 54.5 | <0.0001 |
| Papanicolaous smear | |||||
| Age, year | |||||
| 30–44 | 3,868 | 20.1 | 1,586 | 33.0 | <0.0001 |
| 45–54 | 3,133 | 18.4 | 1,334 | 31.3 | <0.0001 |
| 55–64 | 1,452 | 12.2 | 689 | 23.1 | <0.0001 |
| ≥65 | 1,025 | 7.52 | 475 | 13.9 | <0.0001 |
PSA: prostate specific antigen.
chi-square test.